1. At a Glance – The “Government ka Paisa Kab Aayega?” Story
Krsnaa Diagnostics is currently sitting at a market cap of ~₹1,861 Cr with a stock price of ₹574 — but the real drama isn’t on the stock chart, it’s in their receivables diary. The stock has fallen ~21.6% in 3 months and ~26% in 1 year, which basically means investors are treating it like that one friend who always says “kal de dunga” but never pays.
Despite operating margins of ~30% and a P/E of ~23 (cheaper than peers), the company is stuck in a strange situation: solid business, weak cash conversion. Quarterly sales are ₹159 Cr with PAT at ₹16.5 Cr, but profits dropped ~23.7% QoQ — not because business died, but because the company literally paused operations to recover dues. Yes, you read that right.
Add to this:
- Debt: ₹284 Cr
- Debtor days: 152 days (basically half a year waiting for money)
- ROE: 9.29% (meh)
- EV/EBITDA: 8.9 (tempting but suspiciously cheap)
So here’s the big question:
👉 Is this a hidden gem suffering temporary pain… or a PPP-dependent cash flow nightmare?
2. Introduction – Welcome to the World of “Government Se Paisa Aayega”
Imagine running a business where your biggest customer is the government.
Now imagine that customer pays you… whenever they feel like it.
Welcome to Krsnaa Diagnostics.
This company isn’t your typical Dr Lal Pathlabs or Metropolis. Those guys operate like normal businesses — collect money from patients, run tests, generate cash.
Krsnaa?
It decided to play “public healthcare partner” — meaning it builds diagnostic infrastructure inside government hospitals and then waits patiently for payments.
And patience… is not free.
The company earns ~75% of its revenue from PPP (Public-Private Partnership) contracts. These contracts sound great on paper:
- Long tenure (3–12 years)
- Guaranteed patient footfall
- Annual price escalation
But reality check:
👉 Governments don’t
